Jefferies initiated coverage on Pharming Group N.V. with a new price target
$PHAR
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2024 | $14.00 | Buy | Jefferies |
Jefferies initiated coverage of Pharming Group N.V. with a rating of Buy and set a new price target of $14.00
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
6-K - Pharming Group N.V. (0001828316) (Filer)
Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases. Anurag Relan, M.D., Chief Medical Officer of Pharming, will participate in a fireside chat focused on the hereditary angioedema (HAE) market at 1:50 pm ET / 19:50 CET. To schedule a one-on-one meeting with Pharming's management team, please contact Investor Relations at [email protected] or your Oppenheimer representative. About Pharming Group N.V.Pharming Group N.V. (NASDA
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024Generated US$32.0 million in ca
Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025. Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Wednesday, November 19 at 10:00 GMT/11:00 CET. A live webcast and replay of the presentation can be found in the "Upcoming Events" and "News" sections of Pharming's website. For more information about the conference, or to schedule a one-to-one meeting with Pharming's management team, please contact Investor Relations at [email protected] or your Jefferies representati
Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. ("Pharming" or "the Company") ((Euronext: PHARM, NASDAQ:PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025. Mr. Lynard is a seasoned finance executive with over 20 years of global leadership experience in the life sciences industry, recognized for driving financial and operational transformation across complex, multinational organizations. His appointment follows our strong first half 2025 financial results and marks an important step in strengthening our financial leadership as we continue to execute on our growth strategy. Fabrice Chouraqui, Chief Executive Of
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025. In addition, shareholders also approved the proposal to approve certain components of the remuneration pac
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Fabrice Chouraqui to become Pharming's new Executive Director and Chief Executive Officer, succeeding Sijmen de Vries. Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM). Information regarding the EGM, including the notice to convene, will be shared shortly in a separate press release. Upon the appointment of Mr. Chouraqui, Sijmen de Vries will resign from the Board of Directors.
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024Generated US$32.0 million in ca
Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BI1b6a1a63294c427f91ab7b24a7c6484b Once registered, dial-in information and a unique PIN will be provided, allowing access to
Second quarter 2025 total revenues increased by 26% to US$93.2 million, compared to the second quarter 2024, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue increased by 28% to US$80.4 million, compared to the second quarter 2024, reflecting strong growth in patients and prescribersJoenja® (leniolisib) second quarter revenue increased by 15% to US$12.8 million, compared to the second quarter 2024, with a further acceleration in patient uptakeSecond quarter operating profit amounted to US$10.8 million compared to a US$3.1 million loss in the second quarter 2024Study published in leading peer-reviewed journal Cell identifies new variants leading to PI3Kδ p
SC 13G/A - Pharming Group N.V. (0001828316) (Subject)
SC 13G - Pharming Group N.V. (0001828316) (Subject)
SC 13G - Pharming Group N.V. (0001828316) (Subject)